Key result
This review provides an overview of the biological properties, pharmacological development, and potential therapeutic applications of natural and synthetic large-conductance BK channel activators.
BK channels represent a promising therapeutic target for cardiovascular diseases due to their role in regulating vascular smooth muscle tone.
Highlights potential of BK channel activators in cardiovascular disease; leaves open clinical utility pending prospective trials.
Because of the physiological role played by the hyperpolarisation process resulting from a K(+) outflow, it is not surprising that compounds able to activate outward K(+) channels are considered as promising drugs, with exciting perspectives for the treatment of several cardiovascular, respiratory, neurological and urological diseases. Among the different and numerous K(+) channel families, medicinal chemistry has focused its major interest onto two channel types: the ATP-sensitive channels (K(ATP)) and the large conductance subtype (BK), that belongs to the wide family of calcium-activated K(+) channels. BK channels are almost ubiquitous and exhibit single channel conductance of 100-300 pS, a property which justifies the potent role of these channels in the control of the membrane potential. BK channels have been investigated as potential therapeutic targets for different neuropathies, because of their profound influence on the neuronal activity. Moreover, BK channels are expected to have applications for the therapy of cardiovascular diseases. A potent feed-back control of the vascular and non-vascular smooth muscle tone is mediated by these channels, whose activation can be promoted by both a rise of the intracellular free calcium concentration as well as a membrane depolarisation. Additionally, BK channel activation can also be induced by other factors, such as cAMP-mediated phosphorylation, G-proteins, GMP and cGMP. The aim of this paper is to give a concise overview of the biological and pharmacological properties and potential therapeutic applications of activators of BK channels present at the vascular level. The "state of the art" in the pharmaceutical development of natural and synthetic BK-activators, with a description of the lead chemical structures, will be also described.
No takes yet. Share an insight, caveat, or question.
Vincenzo Calderone (2002) conducted a review in Cardiovascular, respiratory, neurological and urological diseases. BK channel activators was evaluated. This review provides an overview of the biological properties, pharmacological development, and potential therapeutic applications of natural and synthetic large-conductance BK channel activators.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: